Frequently Asked Questions about Mirum Pharmaceuticals, Inc. (MIRM)

Name: Mirum Pharmaceuticals, Inc. (MIRM) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Mirum Pharmaceuticals, Inc. (MIRM) do?

Accepted Answer

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepat...

Question 2

Is Mirum Pharmaceuticals, Inc. (MIRM) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of MIRM reveals an Altman Z-Score of 5.41 and a Piotroski F-Score of 4/9. These metrics, combined with its 5-year revenue trend ($0.52B most recent), help investors decide if MIRM fits their risk profile.

Question 3

What is the current P/E ratio for MIRM?

Accepted Answer

As of the latest trading session, Mirum Pharmaceuticals, Inc. (MIRM) has a trailing P/E ratio of -206.52.

Question 4

Who is the CEO of Mirum Pharmaceuticals, Inc.?

Accepted Answer

The current Chief Executive Officer of Mirum Pharmaceuticals, Inc. is Christopher Peetz.

Question 5

What was MIRM's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Mirum Pharmaceuticals, Inc. reported annual revenues of $0.52B (2025), $0.34B (2024), $0.19B (2023), $0.08B (2022), $0.02B (2021) respectively.

Question 6

Does MIRM pay a dividend?

Accepted Answer

Mirum Pharmaceuticals, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does MIRM have?

Accepted Answer

In its latest reporting period, Mirum Pharmaceuticals, Inc. generated $0.05B in Free Cash Flow against a total debt load of $0.32B.

Question 8

What is the Price-to-Book (P/B) ratio of Mirum Pharmaceuticals, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Mirum Pharmaceuticals, Inc. (MIRM) is currently 15.33.

Question 9

What is the Price-to-Sales (P/S) ratio of MIRM?

Accepted Answer

Based on trailing twelve-month data, Mirum Pharmaceuticals, Inc. (MIRM) trades at a Price-to-Sales (P/S) ratio of 9.26.

Question 10

What is Mirum Pharmaceuticals, Inc.'s Return on Equity (ROE)?

Accepted Answer

Mirum Pharmaceuticals, Inc. (MIRM) has a Return on Equity (ROE) of -8.53%, representing its profitability relative to shareholder equity.

MIRM

18,710 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by SG Americas Securities LLC

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of “Moderate Buy” from Analysts

Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?

Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report?

Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $3,769,800.30 in Stock

Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli